The Prescription Drug Price Relief Act of 2019 was recently introduced to lawmakers, aiming to allow generic drug companies to enter into competition with patent-holding drug manufacturers after a petitioned drug’s price is deemed excessive. With hearings on drug prices under way, all constituents are being heard, from doctors and patients to members of the pharmaceutical industry. The bill would allow the Secretary of Health and Human Services to deem a petitioned drug excessively priced if its U.S. price is higher than that of its median price in the United Kingdom, Canada, Germany, France and Japan. However, if that stipulation is not met, the Secretary can still judge the price excessively high by taking into account factors such as the size of the affected patient population and the value of the drug to patients. Find out more about drug price reform in this feature from Review of Ophthalmology. Read More.